<PubmedArticle><MedlineCitation Status="Publisher" Owner="NLM"><PMID Version="1">39206943</PMID><DateRevised><Year>2024</Year><Month>08</Month><Day>29</Day></DateRevised><Article PubModel="Print-Electronic"><Journal><ISSN IssnType="Electronic">1537-6591</ISSN><JournalIssue CitedMedium="Internet"><PubDate><Year>2024</Year><Month>Aug</Month><Day>29</Day></PubDate></JournalIssue><Title>Clinical infectious diseases : an official publication of the Infectious Diseases Society of America</Title><ISOAbbreviation>Clin Infect Dis</ISOAbbreviation></Journal><ArticleTitle>Efficacy and Safety of Long-Acting Subcutaneous Lenacapavir in Heavily Treatment-Experienced People with Multi-Drug Resistant HIV-1: Week 104 Results of a Phase 2/3 Trial.</ArticleTitle><ELocationID EIdType="pii" ValidYN="Y">ciae423</ELocationID><ELocationID EIdType="doi" ValidYN="Y">10.1093/cid/ciae423</ELocationID><Abstract><AbstractText Label="BACKGROUND" NlmCategory="BACKGROUND">Lenacapavir is a long-acting HIV-1 capsid inhibitor for treatment of HIV-1 infection. We evaluated the efficacy and safety of lenacapavir in combination with an investigator-selected optimized background regimen (OBR) after 104 weeks in adults with multidrug-resistant HIV-1.</AbstractText><AbstractText Label="METHODS" NlmCategory="METHODS">This ongoing, international, Phase 2/3 trial at 42 sites included 72 adults living with multidrug-resistant HIV-1. Following a 2-week oral lenacapavir loading phase, participants received subcutaneous lenacapavir every 26 weeks with an OBR. HIV-1 RNA, CD4 cell counts, and adverse events were assessed over 104 weeks. One participant did not enter the extension phase.</AbstractText><AbstractText Label="RESULTS" NlmCategory="RESULTS">At Week 104, 44 of 71 participants (62%, 95% CI 50; 73) had HIV-1 RNA &lt;50 copies/mL via US Food &amp; Drug Administration (FDA) snapshot algorithm. When missing data (including discontinuations) were excluded, 44 of 54 participants (82%) had HIV-1 RNA &lt;50 copies/mL at Week 104, mean CD4 cell count increased by 122 cells/µL (95% CI 80; 165), and the proportion of participants with CD4 cell count &lt;200 cells/µL decreased from 64% (46 of 72) at Baseline to 29% (16 of 55). Fourteen participants had treatment-emergent lenacapavir resistance; seven resuppressed (HIV-1 RNA &lt;50 copies/mL) while maintaining lenacapavir use. There were no Grade 4 or serious treatment-related adverse events. One participant discontinued study drug due to an injection site reaction.</AbstractText><AbstractText Label="CONCLUSIONS" NlmCategory="CONCLUSIONS">Treatment with subcutaneous lenacapavir in combination with an OBR was well tolerated and resulted in a high rate of virological suppression over 104 weeks. Lenacapavir represents an important treatment option in people with multidrug-resistant HIV-1.</AbstractText><CopyrightInformation>© The Author(s) 2024. Published by Oxford University Press on behalf of Infectious Diseases Society of America. All rights reserved. For commercial re-use, please contact reprints@oup.com for reprints and translation rights for reprints. All other permissions can be obtained through our RightsLink service via the Permissions link on the article page on our site—for further information please contact journals.permissions@oup.com.</CopyrightInformation></Abstract><AuthorList CompleteYN="Y"><Author ValidYN="Y"><LastName>Ogbuagu</LastName><ForeName>Onyema</ForeName><Initials>O</Initials><AffiliationInfo><Affiliation>Yale School of Medicine, New Haven, Connecticut, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Molina</LastName><ForeName>Jean-Michel</ForeName><Initials>JM</Initials><AffiliationInfo><Affiliation>Université de Paris Cité, Paris, France; Département de Maladies Infectieuses, Hôpitaux Saint- Louis, Lariboisière, Assistance Publique Hôpitaux de Paris, Paris, France; INSERM UMR 944, Paris, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Chetchotisakd</LastName><ForeName>Ploenchan</ForeName><Initials>P</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases and Tropical Medicine, Department of Medicine, Faculty of Medicine, Khon Kaen University, Khon Kaen, Thailand.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ramgopal</LastName><ForeName>Moti N</ForeName><Initials>MN</Initials><AffiliationInfo><Affiliation>Midway Immunology &amp; Research Center, Fort Pierce, Florida, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Sanchez</LastName><ForeName>William</ForeName><Initials>W</Initials><AffiliationInfo><Affiliation>Floridian Clinical Research, Miami Lakes, Florida, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Brunetta</LastName><ForeName>Jason</ForeName><Initials>J</Initials><AffiliationInfo><Affiliation>Maple Leaf Medical Clinic, Toronto, ON, Canada.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Castelli</LastName><ForeName>Francesco</ForeName><Initials>F</Initials><AffiliationInfo><Affiliation>Unit of Infectious and Tropical Diseases, University of Brescia and ASST Spedali Civili Hospital, Brescia, Italy.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Crofoot</LastName><ForeName>Gordon E</ForeName><Initials>GE</Initials><AffiliationInfo><Affiliation>The Crofoot Research Center, Houston, Texas, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Hung</LastName><ForeName>Chien-Ching</ForeName><Initials>CC</Initials><AffiliationInfo><Affiliation>Department of Internal Medicine, National Taiwan University Hospital and National Taiwan University College of Medicine, Taipei, Taiwan; Department of Tropical Medicine and Parasitology, National Taiwan University College of Medicine, Taipei, Taiwan; Department of Internal Medicine, National Taiwan University Hospital Yunlin Branch, Yunlin, Taiwan.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Ronot-Bregigeon</LastName><ForeName>Sylvie</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>AP-HM Hôpital Sainte Marguerite, Service Immuno-Hématologie Clinique, Marseille, France.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Margot</LastName><ForeName>Nicolas A</ForeName><Initials>NA</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Wang</LastName><ForeName>Hui</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Dvory-Sobol</LastName><ForeName>Hadas</ForeName><Initials>H</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Rhee</LastName><ForeName>Martin S</ForeName><Initials>MS</Initials><AffiliationInfo><Affiliation>Gilead Sciences, Foster City, California, US.</Affiliation></AffiliationInfo></Author><Author ValidYN="Y"><LastName>Segal-Maurer</LastName><ForeName>Sorana</ForeName><Initials>S</Initials><AffiliationInfo><Affiliation>Division of Infectious Diseases, New York-Presbyterian Queens, Flushing, New York, US.</Affiliation></AffiliationInfo></Author></AuthorList><Language>eng</Language><PublicationTypeList><PublicationType UI="D016428">Journal Article</PublicationType></PublicationTypeList><ArticleDate DateType="Electronic"><Year>2024</Year><Month>08</Month><Day>29</Day></ArticleDate></Article><MedlineJournalInfo><Country>United States</Country><MedlineTA>Clin Infect Dis</MedlineTA><NlmUniqueID>9203213</NlmUniqueID><ISSNLinking>1058-4838</ISSNLinking></MedlineJournalInfo><CitationSubset>IM</CitationSubset><KeywordList Owner="NOTNLM"><Keyword MajorTopicYN="N">HIV-1</Keyword><Keyword MajorTopicYN="N">capsid inhibitor</Keyword><Keyword MajorTopicYN="N">heavily treatment-experienced</Keyword><Keyword MajorTopicYN="N">lenacapavir</Keyword><Keyword MajorTopicYN="N">subcutaneous</Keyword></KeywordList></MedlineCitation><PubmedData><History><PubMedPubDate PubStatus="received"><Year>2024</Year><Month>6</Month><Day>17</Day></PubMedPubDate><PubMedPubDate PubStatus="revised"><Year>2024</Year><Month>7</Month><Day>31</Day></PubMedPubDate><PubMedPubDate PubStatus="accepted"><Year>2024</Year><Month>8</Month><Day>28</Day></PubMedPubDate><PubMedPubDate PubStatus="medline"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="pubmed"><Year>2024</Year><Month>8</Month><Day>31</Day><Hour>9</Hour><Minute>53</Minute></PubMedPubDate><PubMedPubDate PubStatus="entrez"><Year>2024</Year><Month>8</Month><Day>29</Day><Hour>7</Hour><Minute>53</Minute></PubMedPubDate></History><PublicationStatus>aheadofprint</PublicationStatus><ArticleIdList><ArticleId IdType="pubmed">39206943</ArticleId><ArticleId IdType="doi">10.1093/cid/ciae423</ArticleId><ArticleId IdType="pii">7745000</ArticleId></ArticleIdList></PubmedData></PubmedArticle>